These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28120516)

  • 1. Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism.
    Trujillo-Santos J; Bergmann JF; Bortoluzzi C; López-Reyes R; Giorgi-Pierfranceschi M; López-Sáez JB; Ferrazzi P; Bascuñana J; Suriñach JM; Monreal M
    J Thromb Haemost; 2017 Mar; 15(3):429-438. PubMed ID: 28120516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients.
    Fuller K; Malecki S; Anselmo L; Borrego ME; Jakeman B; Burnett A
    Ann Pharmacother; 2018 Mar; 52(3):257-262. PubMed ID: 29025276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
    Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
    Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
    Trujillo-Santos J; Di Micco P; Dentali F; Douketis J; Díaz-Peromingo JA; Núñez MJ; Cañas I; Mastroiacovo D; Saraiva de Sousa M; Monreal M;
    Thromb Haemost; 2017 Jan; 117(2):382-389. PubMed ID: 27786333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
    J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
    Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3).
    Eriksson BI; Agnelli G; Gallus AS; Lassen MR; Prins MH; Renfurm RW; Kashiwa M; Turpie AG
    Thromb Haemost; 2014 Feb; 111(2):213-25. PubMed ID: 24136153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
    JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Once- versus Twice-Daily Enoxaparin Prophylaxis on Risk for Venous Thromboembolism and Clinically Relevant Bleeding.
    Pannucci CJ; Fleming KI; Agarwal J; Rockwell WB; Prazak AM; Momeni A
    Plast Reconstr Surg; 2018 Jul; 142(1):239-249. PubMed ID: 29649055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
    Couturaud F; Julian JA; Kearon C
    Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once daily enoxaparin for outpatient treatment of acute venous thromboembolism: a case-control study.
    Hacobian M; Shetty R; Niles CM; Gerhard-Herman M; Vallurupalli N; Baroletti S; McKean SC; Sonis J; Parasuraman S; Kosowsky JM; Goldhaber SZ
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):21-5. PubMed ID: 19147527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
    Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once daily versus twice daily enoxaparin for acute pulmonary embolism in cancer patients.
    King AC; Ma MQ; Chisholm G; Toale KM
    J Oncol Pharm Pract; 2016 Apr; 22(2):265-70. PubMed ID: 25888639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
    Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT
    J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enoxaparin versus tinzaparin for venous thromboembolic prophylaxis during rehabilitation after acute spinal cord injury: a retrospective cohort study comparing safety and efficacy.
    Marciniak CM; Kaplan J; Welty L; Chen D
    PM R; 2012 Jan; 4(1):11-7. PubMed ID: 22269449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients.
    Laporte S; Liotier J; Bertoletti L; Kleber FX; Pineo GF; Chapelle C; Moulin N; Mismetti P
    J Thromb Haemost; 2011 Mar; 9(3):464-72. PubMed ID: 21232002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
    Fuji T; Ochi T; Niwa S; Fujita S
    J Orthop Sci; 2008 Sep; 13(5):442-51. PubMed ID: 18843459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
    Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
    JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
    Senay A; Trottier M; Delisle J; Banica A; Benoit B; Laflamme GY; Malo M; Nguyen H; Ranger P; Fernandes JC
    Vasc Health Risk Manag; 2018; 14():81-89. PubMed ID: 29780248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.